French drug assessment center demands suspension of four COVID vaccines from rollout

The following report was released by the Centre territorial d’Information indépendante et d’Avis pharmaceutiques (CTIAP) last April 2, 2021. It is a report showing that four of the top COVID vaccines being used in rollouts have not received sufficient clinical testing, and the quality of their active substances and their manufacturing processes are problematic. As the active substances used in the four vaccines, Pfizer/BioNTech, Moderna, Astra Zeneca, and Janssen (made by Johnson & Johnson) are all new, CTIAP says that they should have been subjected to a separate safety and efficacy review, before they were used to make the vaccines.

The CTIAP calls into question the prolonged submission of “confirmation of efficacy, safety, and tolerance” of the vaccine. The report states, “This time limit no longer only concerns the clinical trials in progress, but also the “‘quality evidence for the active substance and the finished product’ itself: that is to say the intrinsic quality (the heart) of the product sold and administered to millions of people”. The CTIAP also asserts that the “official documents published also underline the incomplete nature of the evidence relating to the ‘quality’ of the ‘active substance’ and of the ‘excipients’, of the ‘manufacturing process’, of the ‘reproducibility of the batches’ marketed”.

The CTIAP goes on to say that free, prior, and informed consent cannot be achieved as people have not been informed of the anomalies in the vaccine production and rollout. People who have been vaccinated now be told of their findings. Moreover, CTIAP says that the “vaccine obligation” as being purported by the “vaccination pass” cannot flourish as a result of the concerns they have raised.

In light of the adverse effects and deaths following vaccination being recorded in France and Europe, CTIAP asserts that “in all countries where these vaccines against COVID-19 have been marketed, all the batches thus “released” [must be] withdrawn immediately; and that these MAs [Marketing Authorizations] which have been granted, [must] be suspended, or even canceled, as a matter of urgency until further notice”.

Editor’s Note: This report from the CTIAP shows us the extent of anomalies surrounding the rapid deployment of COVID vaccines. Why were these not reviewed by drug regulators in the US and UK? Why were countries allowed to vaccinate without due diligence? What did the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization COVAX facility review when they assessed these vaccines? Why do they need to cut corners, when they knew that the failure to assure the safety of these experimental vaccines could potentially lead to a new health crisis?

The safety of vaccine recipients has been compromised because drug regulators rushed to give these vaccines emergency use authorizations. The worst part is that they gave vaccine manufacturers immunity from liability. They cannot tell us that this is not about profit – not when we know that COVID is harmless to most people, and when early treatment protocols using cheap, accessible drugs are being blocked by these same organizations. [See CDC updates planning scenarios, shows IFR lower than flu and articles in Is It Really That Deadly? Also, read articles under Treatment for COVID-19].